10 Best Undervalued High Quality Stocks With Great Momentum for October 2025
Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io
Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.
Market Overview & Selection Criteria
The current market environment presents a mix of opportunities and challenges for investors seeking growth and value. Our selection process emphasizes companies with strong fundamentals, robust free cash flow, high return on invested capital (ROIC), and attractive valuation metrics. We prioritize firms with a track record of revenue growth, healthy margins, and manageable debt levels. Each stock in this watchlist is evaluated using ValueSense’s proprietary quality rating and intrinsic value models, ensuring a balanced approach across sectors—technology, healthcare, consumer staples, and industrials.
Featured Stock Analysis
Stock #1: Taiwan Semiconductor Manufacturing Company Limited (TSM)
| Metric | Value |
|---|---|
| Market Cap | $1,554.9B |
| Quality Rating | 8.3 |
| Intrinsic Value | $398.9 |
| 1Y Return | 60.3% |
| Revenue | NT$3,401.2B |
| Free Cash Flow | NT$947.9B |
| Revenue Growth | 39.5% |
| FCF margin | 27.9% |
| Gross margin | 58.6% |
| ROIC | 34.6% |
| Total Debt to Equity | 0.0% |
Investment Thesis
Taiwan Semiconductor Manufacturing Company (TSM) stands as a global leader in semiconductor fabrication, benefiting from secular growth in AI, 5G, and high-performance computing. With a market cap of $1,554.9B, TSM boasts a stellar quality rating of 8.3 and an intrinsic value estimate of $398.9. The company delivered a remarkable 60.3% one-year return, driven by 39.5% revenue growth and industry-leading gross margins of 58.6%. TSM’s free cash flow margin of 27.9% and ROIC of 34.6% underscore its operational excellence and capital efficiency. Notably, the company carries no debt, positioning it well for continued investment in next-generation technologies.
Key Catalysts
- Dominant position in advanced semiconductor manufacturing
- Strong demand from AI and data center markets
- High revenue growth and exceptional profitability
- Zero debt on the balance sheet
Risk Factors
- Geopolitical risks related to operations in Taiwan
- Cyclicality in the semiconductor industry
- Intense competition and high capital expenditure requirements
Stock #2: SAP SE (SAP)
| Metric | Value |
|---|---|
| Market Cap | $314.8B |
| Quality Rating | 6.9 |
| Intrinsic Value | $309.2 |
| 1Y Return | 17.6% |
| Revenue | €35.9B |
| Free Cash Flow | €6,491.0M |
| Revenue Growth | 10.3% |
| FCF margin | 18.1% |
| Gross margin | 73.5% |
| ROIC | 15.1% |
| Total Debt to Equity | 21.2% |
Investment Thesis
SAP SE, a European software giant with a $314.8B market cap, is transitioning its business to cloud-based solutions, reflected in its 10.3% revenue growth. The company’s quality rating of 6.9 and intrinsic value of $309.2 highlight its solid fundamentals. SAP’s gross margin of 73.5% is among the highest in enterprise software, while its 18.1% free cash flow margin and 15.1% ROIC demonstrate efficient capital allocation. With moderate debt (21.2% debt-to-equity), SAP is well-positioned to capitalize on digital transformation trends.
Key Catalysts
- Accelerating cloud revenue growth
- High gross and free cash flow margins
- Strong global customer base in enterprise software
Risk Factors
- Execution risks in cloud transition
- Competitive pressures from other SaaS providers
- Currency exposure due to global operations
Stock #3: Cisco Systems, Inc. (CSCO)
| Metric | Value |
|---|---|
| Market Cap | $273.6B |
| Quality Rating | 6.9 |
| Intrinsic Value | $77.8 |
| 1Y Return | 23.4% |
| Revenue | $56.7B |
| Free Cash Flow | $13.3B |
| Revenue Growth | 5.3% |
| FCF margin | 23.5% |
| Gross margin | 65.1% |
| ROIC | 13.3% |
| Total Debt to Equity | 63.3% |
Investment Thesis
Cisco Systems (CSCO), with a $273.6B market cap, remains a cornerstone of global networking infrastructure. The company’s quality rating of 6.9 and intrinsic value of $77.8 reflect steady performance, supported by 5.3% revenue growth and a 23.5% free cash flow margin. CSCO’s gross margin of 65.1% and ROIC of 13.3% are solid, though its higher debt-to-equity ratio 63.3% warrants attention. Cisco’s recurring software and services revenue is becoming a larger part of its business, providing stability amid hardware cyclicality.
Key Catalysts
- Shift toward software and subscription revenue
- Strong cash generation and shareholder returns
- Leading position in enterprise networking
Risk Factors
- Slower growth in core hardware markets
- Elevated debt levels
- Intense competition in cloud and security
Stock #4: Novartis AG (NVS)
| Metric | Value |
|---|---|
| Market Cap | $254.7B |
| Quality Rating | 7.3 |
| Intrinsic Value | $141.9 |
| 1Y Return | 12.2% |
| Revenue | $54.6B |
| Free Cash Flow | $16.8B |
| Revenue Growth | 13.3% |
| FCF margin | 30.8% |
| Gross margin | 56.0% |
| ROIC | 20.0% |
| Total Debt to Equity | 77.6% |
Investment Thesis
Novartis AG (NVS), a $254.7B pharmaceutical leader, combines innovation with financial discipline. The company’s quality rating of 7.3 and intrinsic value of $141.9 are supported by 13.3% revenue growth and a 30.8% free cash flow margin. NVS’s gross margin of 56.0% and ROIC of 20.0% reflect its ability to monetize a robust pipeline, though its debt-to-equity ratio of 77.6% is on the higher side. Novartis’s focus on high-margin specialty drugs and cost controls positions it well for sustained growth.
Key Catalysts
- Strong pipeline of innovative therapies
- High free cash flow conversion
- Global reach in pharmaceuticals
Risk Factors
- Patent expirations on key drugs
- Regulatory and pricing pressures
- Elevated leverage
Stock #5: Micron Technology, Inc. (MU)
| Metric | Value |
|---|---|
| Market Cap | $226.0B |
| Quality Rating | 8.4 |
| Intrinsic Value | $333.8 |
| 1Y Return | 85.6% |
| Revenue | $37.4B |
| Free Cash Flow | $8,929.0M |
| Revenue Growth | 48.9% |
| FCF margin | 23.9% |
| Gross margin | 39.8% |
| ROIC | 19.6% |
| Total Debt to Equity | 28.5% |
Investment Thesis
Micron Technology (MU), with a $226.0B market cap, is a leading memory chip producer benefiting from AI and data center demand. MU’s quality rating of 8.4 and intrinsic value of $333.8 are among the highest in this watchlist, supported by 48.9% revenue growth and an 85.6% one-year return. The company’s 23.9% free cash flow margin, 39.8% gross margin, and 19.6% ROIC reflect strong execution, while its 28.5% debt-to-equity ratio is manageable for the sector.
Key Catalysts
- Exposure to AI and high-performance computing
- Rapid revenue and earnings growth
- Improving balance sheet and cash flow
Risk Factors
- Cyclicality in memory chip pricing
- Capital intensity and technology risks
- Geopolitical supply chain concerns
Stock #6: Abbott Laboratories (ABT)
| Metric | Value |
|---|---|
| Market Cap | $222.1B |
| Quality Rating | 6.9 |
| Intrinsic Value | $152.6 |
| 1Y Return | 8.9% |
| Revenue | $43.8B |
| Free Cash Flow | $4,626.0M |
| Revenue Growth | 6.4% |
| FCF margin | 10.6% |
| Gross margin | 55.0% |
| ROIC | 25.0% |
| Total Debt to Equity | N/A |
Investment Thesis
Abbott Laboratories (ABT), a $222.1B healthcare conglomerate, delivers steady growth with a 6.4% revenue increase and a quality rating of 6.9. The company’s intrinsic value of $152.6 is supported by a 10.6% free cash flow margin and an impressive 25.0% ROIC. ABT’s gross margin of 55.0% reflects its diversified portfolio across diagnostics, medical devices, and nutrition. Debt metrics are not specified, but Abbott’s consistent performance and innovation in healthcare underpin its investment case.
Key Catalysts
- Diversified healthcare portfolio
- Strong ROIC and cash generation
- Innovation in diagnostics and devices
Risk Factors
- Regulatory scrutiny in healthcare
- Competition in core markets
- Potential supply chain disruptions
Stock #7: Uber Technologies, Inc. (UBER)
| Metric | Value |
|---|---|
| Market Cap | $193.5B |
| Quality Rating | 7.4 |
| Intrinsic Value | $204.8 |
| 1Y Return | 13.0% |
| Revenue | $47.3B |
| Free Cash Flow | $8,540.0M |
| Revenue Growth | 18.2% |
| FCF margin | 18.0% |
| Gross margin | 39.7% |
| ROIC | 66.4% |
| Total Debt to Equity | 52.2% |
Investment Thesis
Uber Technologies (UBER), valued at $193.5B, is transforming global mobility and delivery. The company’s quality rating of 7.4 and intrinsic value of $204.8 reflect improving fundamentals, with 18.2% revenue growth and a 66.4% ROIC. UBER’s 18.0% free cash flow margin and 39.7% gross margin signal operational leverage as scale increases. Debt-to-equity stands at 52.2%, which is moderate for a growth company. Uber’s platform strength and expanding margins make it a standout in the gig economy.
Key Catalysts
- Leading position in ride-hailing and delivery
- Rapid revenue growth and improving profitability
- High return on invested capital
Risk Factors
- Regulatory challenges in key markets
- Competitive intensity
- Exposure to macroeconomic cycles
Stock #8: Unilever PLC (UL)
| Metric | Value |
|---|---|
| Market Cap | $153.4B |
| Quality Rating | 7.3 |
| Intrinsic Value | $97.8 |
| 1Y Return | -0.2% |
| Revenue | €120.1B |
| Free Cash Flow | €14.5B |
| Revenue Growth | 2.5% |
| FCF margin | 12.1% |
| Gross margin | 71.3% |
| ROIC | 32.1% |
| Total Debt to Equity | 160.7% |
Investment Thesis
Unilever PLC (UL), with a $153.4B market cap, is a global consumer staples leader. The company’s quality rating of 7.3 and intrinsic value of $97.8 are supported by a 71.3% gross margin and 32.1% ROIC. Revenue growth is modest at 2.5%, but UL’s 12.1% free cash flow margin and strong brand portfolio provide stability. The high debt-to-equity ratio of 160.7% is a notable concern, but Unilever’s defensive characteristics and global reach remain attractive.
Key Catalysts
- Iconic global brands
- High gross margin and ROIC
- Defensive earnings profile
Risk Factors
- Sluggish revenue growth
- Elevated leverage
- Input cost inflation
Stock #9: Anheuser-Busch InBev SA/NV (BUD)
| Metric | Value |
|---|---|
| Market Cap | $122.7B |
| Quality Rating | 7.1 |
| Intrinsic Value | $72.8 |
| 1Y Return | -5.8% |
| Revenue | $73.5B |
| Free Cash Flow | $11.7B |
| Revenue Growth | 22.7% |
| FCF margin | 15.9% |
| Gross margin | 55.7% |
| ROIC | 17.3% |
| Total Debt to Equity | 82.7% |
Investment Thesis
Anheuser-Busch InBev (BUD), a $122.7B brewer, combines scale with 22.7% revenue growth and a quality rating of 7.1. The company’s intrinsic value of $72.8 is supported by a 15.9% free cash flow margin and 17.3% ROIC. BUD’s gross margin of 55.7% reflects pricing power, though its debt-to-equity ratio of 82.7% is elevated. The company’s global footprint and premiumization strategy underpin its long-term outlook.
Key Catalysts
- Leading global beer portfolio
- Strong free cash flow generation
- Premiumization and cost initiatives
Risk Factors
- High debt levels
- Regulatory and tax challenges
- Changing consumer preferences
Stock #10: Medtronic plc (MDT)
| Metric | Value |
|---|---|
| Market Cap | $121.8B |
| Quality Rating | 6.7 |
| Intrinsic Value | $123.2 |
| 1Y Return | 6.5% |
| Revenue | $34.2B |
| Free Cash Flow | $5,303.0M |
| Revenue Growth | 5.0% |
| FCF margin | 15.5% |
| Gross margin | 63.4% |
| ROIC | 8.2% |
| Total Debt to Equity | 59.4% |
Investment Thesis
Medtronic plc (MDT), a $121.8B medical technology company, offers stability with a 5.0% revenue increase and a quality rating of 6.7. The company’s intrinsic value of $123.2 is supported by a 15.5% free cash flow margin and 63.4% gross margin. MDT’s ROIC of 8.2% is modest, and its debt-to-equity ratio of 59.4% is manageable. Medtronic’s innovation in medical devices and global presence provide a defensive growth profile.
Key Catalysts
- Leading position in medical devices
- Steady cash flow and margins
- Global healthcare infrastructure exposure
Risk Factors
- Moderate growth prospects
- Regulatory and reimbursement risks
- Competitive pressures
Portfolio Diversification Insights
This watchlist spans technology (TSM, SAP, CSCO, MU), healthcare (NVS, ABT, MDT), consumer staples (UL, BUD), and the gig economy (UBER), offering broad sector exposure. The allocation emphasizes companies with strong cash generation, high returns on capital, and reasonable valuations. Such diversification helps mitigate sector-specific risks while capturing growth across multiple themes—semiconductors, cloud software, healthcare innovation, and global consumer brands.
Market Timing & Entry Strategies
While timing the market is inherently challenging, investors may consider dollar-cost averaging into these positions, especially during periods of broader market weakness or sector-specific pullbacks. Focus on companies where the current price is meaningfully below the intrinsic value estimate, and monitor key catalysts and risk factors for each stock. A disciplined, research-driven approach—rather than chasing short-term momentum—is more likely to yield sustainable returns over time.
Explore More Investment Opportunities
For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:
📌 50 Undervalued Stocks (Best overall value plays for 2025)
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)
🔍 Check out these stocks on the Value Sense platform for free!
More Articles You Might Like
- 10 Best Price Dislocation Undervalued Low Momentum Stocks for October 2025
- 10 Best High Growth Stocks With Great Momentum for October 2025
- 10 Best Undervalued Stocks With Great Momentum for October 2025
- 10 Best High Quality Stocks With Great Momentum for October 2025
- 10 Best Great Momentum Stocks for October 2025
FAQ Section
How were these stocks selected?
These stocks were chosen based on ValueSense’s proprietary quality and intrinsic value metrics, emphasizing companies with strong fundamentals, robust cash flow, high returns on capital, and reasonable valuations across multiple sectors.
What's the best stock from this list?
While each stock has unique strengths, Taiwan Semiconductor Manufacturing Company (TSM) and Micron Technology (MU) stand out for their exceptional growth, profitability, and quality ratings. However, the “best” stock depends on your investment goals, risk tolerance, and time horizon.
Should I buy all these stocks or diversify?
Diversification is a core principle of sound investing. While this watchlist is already diversified across sectors, investors should further tailor their portfolios based on individual risk profiles and financial objectives.
What are the biggest risks with these picks?
Key risks include sector cyclicality (especially in tech and semiconductors), regulatory challenges (healthcare and consumer staples), elevated debt levels (some consumer and healthcare names), and macroeconomic uncertainties affecting global growth.
When is the best time to invest in these stocks?
Consider building positions gradually, especially during market pullbacks or when individual stocks trade below their intrinsic value estimates. Avoid trying to time the market perfectly; focus on long-term fundamentals and valuation.
This article is for educational purposes only and does not constitute investment advice. Always conduct your own research or consult a financial advisor before making investment decisions. For more stock analysis and research tools, visit ValueSense.